ipilimumab

Known as: MOAB-CTLA-4, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, monoclonal antibody CTLA-4 
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
OBJECTIVES Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive… (More)
Is this relevant?
Review
2016
Review
2016
In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PURPOSE To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?